Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2021-07-14 00:00:00 ET · period of report 2021-07-12 · accession 0001735276-21-000053 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-07-14 | 2021-07-12 | ALNY | KEATING LAURIE | EVP, CLO | M - OptEx | $87.90 | +6,812 | 11.9K | +133% | +$598.8K |
| DM | 2021-07-14 | 2021-07-12 | ALNY | KEATING LAURIE | EVP, CLO | S - Sale+OE | $178.96 | -6,812 | 10.1K | -40% | -$1.22M |
| DM | 2021-07-14 | 2021-07-12 | ALNY | KEATING LAURIE | EVP, CLO | M - OptEx | $0.00 | -6,812 | 17.2K | -28% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-12 | M | A | 1,812 | $85.00 | 6,944 | D | — | — | |
| 2 | Common | Common Stock | 2021-07-12 | S | D | 5,000 | $178.95 | 5,132 | D | — | — | |
| 3 | Common | Common Stock | 2021-07-12 | S | D | 1,812 | $179.00 | 10,132 | D | — | — | |
| 4 | Common | Common Stock | 2021-07-12 | M | A | 5,000 | $88.95 | 11,944 | D | — | — | |
| 5 | Derivative | Stock Option (right to buy) | 2021-07-12 | M | D | 5,000 | $0.00 | 9,000 | D | $88.95 · — to 2025-12-18 | 5,000 Common Stock | (F3) The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |
| 6 | Derivative | Stock Option (right to buy) | 2021-07-12 | M | D | 1,812 | $0.00 | 17,188 | D | $85.00 · — to 2029-02-27 | 1,812 Common Stock | (F3) The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |